Finanzen von Bio-Techne Corp (TECH)TECHBio-Techne Corp

Bio-Techne Corporation (TECH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 82.6% of total sales, equivalent to $257.34M. Other significant revenue streams include Instruments and Service. Understanding this composition is critical for investors evaluating how TECH navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Bio-Techne Corporation maintains a gross margin of 66.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.85%, while the net margin is 17.01%. These profitability ratios, combined with a Return on Equity (ROE) of 9.03%, provide a clear picture of how effectively TECH converts its operational activities into shareholder value.

In the context of the broader market, TECH competes directly with industry leaders such as ELAN and PCVX. With a market capitalization of $11.38B, it holds a significant position in the sector. When comparing efficiency, TECH's gross margin of 66.02% stands against ELAN's 48.17% and PCVX's N/A. Such benchmarking helps identify whether Bio-Techne Corporation is trading at a premium or discount relative to its financial performance.

The company has shown a recovery in profitability with a net profit of $54.622 million for Q4 FY2026, translating to an EPS of $0.35, a significant improvement from a net loss of $17.677 million in the same quarter last year.